BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/16/2020 11:58:14 PM | Browse: 1038 | Download: 2134
 |
Received |
|
2019-11-01 05:43 |
|
Peer-Review Started |
|
2019-11-01 05:43 |
|
First Decision by Editorial Office Director |
|
2019-11-21 01:04 |
|
Return for Revision |
|
2019-11-21 01:04 |
|
Revised |
|
2019-12-06 15:55 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-02-20 10:25 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-02-23 22:42 |
|
Articles in Press |
|
2020-02-23 22:42 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-03-13 08:39 |
|
Publish the Manuscript Online |
|
2020-03-16 23:58 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Efficacy, patterns of use and cost of Pertuzumab in the treatment of HER2+ metastatic breast cancer in Singapore: The National Cancer Centre Singapore experience
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sylwan Rahardja, Ryan Ying Cong Tan, Rehena Sultana, Fun Loon Leong and Elaine Hsuen Lim |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Sylwan Rahardja, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, Singapore 119228, Singapore. sylwanrahardja@gmail.com |
| Key Words |
Pertuzumab; Chemotherapy; Metastatic breast cancer; Treatment cost; ; |
| Core Tip |
Pertuzumab is a humanized anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody found in a Phase III clinical trial to significantly improve median survival in HER2 positive metastatic breast cancer when used in combination with a taxane and Trastuzumab, and its clinical efficacy has transformed the therapeutic landscape of HER2-positive breast cancer. In our study, there was a statistically significant difference in the median overall survival between Pertuzumab and non-Pertuzumab groups [51.5 (95%CI: 35.8–60.0) vs 32.9 (95%CI: 28.1–37.5) mo; P = 0.0128] while the rate of grade 3 cardiotoxicity was low (4.88%). However, costs remain high. |
| Publish Date |
2020-03-16 23:58 |
| Citation |
Rahardja S, Tan RYC, Sultana R, Leong FL, Lim EH. Efficacy, patterns of use and cost of Pertuzumab in the treatment of HER2+ metastatic breast cancer in Singapore: The National Cancer Centre Singapore experience. World J Clin Oncol 2020; 11(3): 143-151 |
| URL |
https://www.wjgnet.com/2218-4333/full/v11/i3/143.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v11.i3.143 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
